Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial
Authors
Keywords
-
Journal
NATURE MEDICINE
Volume 27, Issue 12, Pages 2200-2211
Publisher
Springer Science and Business Media LLC
Online
2021-12-11
DOI
10.1038/s41591-021-01579-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition
- (2021) Kevin Litchfield et al. CELL
- CXCL9-expressing tumor-associated macrophages: new players in the fight against cancer
- (2021) Paola Marie Marcovecchio et al. Journal for ImmunoTherapy of Cancer
- The Immunoscore in Localized Urothelial Carcinoma Treated with Neoadjuvant Chemotherapy: Clinical Significance for Pathologic Responses and Overall Survival
- (2021) Elise F. Nassif et al. Cancers
- Myeloid Cell–associated Resistance to PD-1/PD-L1 Blockade in Urothelial Cancer Revealed Through Bulk and Single-cell RNA Sequencing
- (2021) Li Wang et al. CLINICAL CANCER RESEARCH
- Cross-platform comparison of immune-related gene expression to assess intratumor immune responses following cancer immunotherapy
- (2021) Li Zhang et al. JOURNAL OF IMMUNOLOGICAL METHODS
- The repertoire of mutational signatures in human cancer
- (2020) Ludmil B. Alexandrov et al. NATURE
- Hepatocellular Carcinoma Cells Upregulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice
- (2020) David Kung-Chun Chiu et al. GASTROENTEROLOGY
- Tumor, immune, and stromal characteristics associated with clinical outcomes with atezolizumab (atezo) + platinum-based chemotherapy (PBC) or atezo monotherapy (mono) versus PBC in metastatic urothelial cancer (mUC) from the phase III IMvigor130 study.
- (2020) Matt D. Galsky et al. JOURNAL OF CLINICAL ONCOLOGY
- High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade
- (2020) Kobe C. Yuen et al. NATURE MEDICINE
- Cytotoxic T-cell-related gene expression signature predicts improved survival in muscle-invasive urothelial bladder cancer patients after radical cystectomy and adjuvant chemotherapy
- (2020) Markus Eckstein et al. Journal for ImmunoTherapy of Cancer
- Clinical development of therapies targeting TGFβ: current knowledge and future perspectives.
- (2020) D. Ciardiello et al. ANNALS OF ONCOLOGY
- Molecular Origins of APOBEC-Associated Mutations in Cancer
- (2020) Mia Petljak et al. DNA REPAIR
- The immunotherapy revolution in genitourinary malignancies
- (2020) Shruti U Gandhy et al. Immunotherapy
- APOBEC3A catalyzes mutation and drives carcinogenesis in vivo
- (2020) Emily K. Law et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
- (2020) Thomas Powles et al. LANCET ONCOLOGY
- Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial
- (2020) Robert J. Motzer et al. NATURE MEDICINE
- Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
- (2020) Thomas Powles et al. NEW ENGLAND JOURNAL OF MEDICINE
- Baseline Frequency of Inflammatory Cxcl9-Expressing Tumor-Associated Macrophages Predicts Response to Avelumab Treatment
- (2020) Yan Qu et al. Cell Reports
- Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis
- (2020) Andrea B Apolo et al. Journal for ImmunoTherapy of Cancer
- Hot or Not: Tumor Mutational Burden (TMB) as a Biomarker of Immunotherapy Response in Genitourinary Cancers
- (2020) Brian Halbert et al. UROLOGY
- A multifactorial model of T cell expansion and durable clinical benefit in response to a PD-L1 inhibitor
- (2019) Mark D. M. Leiserson et al. PLoS One
- Single-Cell Transcriptomics of Human and Mouse Lung Cancers Reveals Conserved Myeloid Populations across Individuals and Species
- (2019) Rapolas Zilionis et al. IMMUNITY
- Reliable Gene Expression Profiling from Small and Hematoxylin and Eosin–Stained Clinical Formalin-Fixed, Paraffin-Embedded Specimens Using the HTG EdgeSeq Platform
- (2019) Zhenhao Qi et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling
- (2019) Brian D. Robinson et al. Nature Communications
- Concordance among four commercially available, validated programmed cell death ligand-1 assays in urothelial carcinoma
- (2019) Magdalena Zajac et al. Diagnostic Pathology
- Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial
- (2019) Thomas Powles et al. NATURE MEDICINE
- The evolving role of PD-L1 testing in patients with metastatic urothelial carcinoma
- (2019) Thomas Powles et al. CANCER TREATMENT REVIEWS
- TIGIT as an emerging immune checkpoint
- (2019) H. Harjunpää et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation – A target for novel cancer therapy
- (2018) Ryuma Tokunaga et al. CANCER TREATMENT REVIEWS
- Interferon Gamma Messenger RNA Signature in Tumor Biopsies Predicts Outcomes in Patients with Non–Small Cell Lung Carcinoma or Urothelial Cancer Treated with Durvalumab
- (2018) Brandon W. Higgs et al. CLINICAL CANCER RESEARCH
- The Immune Landscape of Cancer
- (2018) Vésteinn Thorsson et al. IMMUNITY
- Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers
- (2018) Min Yuen Teo et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
- (2018) Thomas Powles et al. LANCET
- TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
- (2018) Sanjeev Mariathasan et al. NATURE
- Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study
- (2018) Andrea Necchi et al. JOURNAL OF CLINICAL ONCOLOGY
- APOBEC-related mutagenesis and neo-peptide hydrophobicity: implications for response to immunotherapy
- (2018) Amélie Boichard et al. OncoImmunology
- IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
- (2017) Mark Ayers et al. JOURNAL OF CLINICAL INVESTIGATION
- First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
- (2017) Arjun V Balar et al. LANCET ONCOLOGY
- Elements of cancer immunity and the cancer–immune set point
- (2017) Daniel S. Chen et al. NATURE
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- (2017) Joaquim Bellmunt et al. NEW ENGLAND JOURNAL OF MEDICINE
- APOBEC-mediated mutagenesis in urothelial carcinoma is associated with improved survival, mutations in DNA damage response genes, and immune response
- (2017) Alexander P. Glaser et al. Oncotarget
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
- (2016) Louis Fehrenbacher et al. LANCET
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma
- (2016) Stephanie A. Mullane et al. Scientific Reports
- Mouse and human FcR effector functions
- (2015) Pierre Bruhns et al. IMMUNOLOGICAL REVIEWS
- Biomarker: Predictive or Prognostic?
- (2015) Karla V. Ballman JOURNAL OF CLINICAL ONCOLOGY
- Robust enumeration of cell subsets from tissue expression profiles
- (2015) Aaron M Newman et al. NATURE METHODS
- Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells
- (2015) B. Boyerinas et al. Cancer Immunology Research
- The Molecular Signatures Database Hallmark Gene Set Collection
- (2015) Arthur Liberzon et al. Cell Systems
- Regularization Paths for Generalized Linear Models via Coordinate Descent
- (2015) Jerome Friedman et al. Journal of Statistical Software
- Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
- (2013) Garrett M Frampton et al. NATURE BIOTECHNOLOGY
- 12-Chemokine Gene Signature Identifies Lymph Node-like Structures in Melanoma: Potential for Patient Selection for Immunotherapy?
- (2012) Jane L. Messina et al. Scientific Reports
- Roles of Fibroblast Growth Factor Receptors in Carcinogenesis
- (2010) E. M. Haugsten et al. MOLECULAR CANCER RESEARCH
- WGCNA: an R package for weighted correlation network analysis
- (2008) Peter Langfelder et al. BMC BIOINFORMATICS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now